MKL1 antisera for leukemia research

Technology #cu14245

Leukemia was responsible for 9.5% of cancer deaths in 2010, and from 1999 to 2006, the survival rate for patients diagnosed with leukemia was as low as 55%, underscoring the deadly impact of this disease. Although much progress has been made in understanding this cancer in the past half century, our ability to diagnose and study the causes of leukemia remain hindered by a lack of reliable biomarkers for all aspects of the disease. MKL1 is a gene whose aberrant expression is known to be involved in certain types of leukemias. This technology offers antisera that can be used to detect MKL1.

Reliable immunoprecipitation and immunohistochemistry with MKL1 antisera

MKL1 antisera were generated in rabbit using a recombinant MKL1 protein fragment. The resulting antisera have demonstrated very robust results when used for immunoprecipitation of human MKL1, but can also be used to visualize the location of MKL1 for research purposes in human and mouse cell lines.

MKL1 antisera have been tested for immunoprecipitation, western blot and EMSA applications.

Lead Inventor:
Ron Prywes, Ph.D.

Applications:
• Research tool for MKL1-based leukemia

Advantages:
• Highly specific for MKL-1
Patent information:
N/A
Tech Ventures Reference: IR CU14245

Related Publications:


Inventors

Ronald Michael Prywes